346 589

Cited 5 times in

Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer

Authors
 Hong Jae Chon  ;  Sun Young Rha  ;  Hyung Soon Park  ;  Sang Joon Shin  ;  Hyo Song Kim  ;  Jae Kyung Roh  ;  Sung Hoon Noh  ;  Hyun Cheol Chung  ;  Hei-Cheul Jeung 
Citation
 CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.68(4) : 991-999, 2011 
Journal Title
CANCER CHEMOTHERAPY AND PHARMACOLOGY
ISSN
 0344-5704 
Issue Date
2011
MeSH
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Diarrhea/chemically induced ; Disease-Free Survival ; Drug Combinations ; Female ; Humans ; Male ; Middle Aged ; Neutropenia/chemically induced ; Oxonic Acid/administration & dosage ; Patient Selection ; Salvage Therapy/methods* ; Serum Albumin/metabolism* ; Stomach Neoplasms/drug therapy* ; Stomach Neoplasms/pathology ; Survival ; Tegafur/administration & dosage ; Treatment Outcome
Keywords
Gastric cancer ; Chemotherapy ; Clinical trial ; S-1 ; Irinotecan
Abstract
PURPOSE: This phase II trial first describes the combination chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) for pretreated advanced gastric cancer (AGC) patients.

METHODS: Patients who had previously been treated with greater than or equal to one regimen were enrolled. They received S-1 35 mg/m(2) twice daily on days 1-14 and irinotecan 150 mg/m(2) on days 1 and 15, every 4 weeks. The primary endpoint was overall survival (OS).

RESULTS: Among the 38 patients enrolled, 18 patients were treated as second line, and the remaining 20 patients were enrolled as third- or fourth line. A total of 208 cycles were administered with the median being four cycles (range 1-16). The median OS was 8.7 months [95% confidence interval (CI) 7.5-10.3], and the median progression-free survival was 6.3 months (95% CI 5.3-7.3). Low serum albumin (<3.5 mg/dL) was an independent adverse prognosticator for survival. Overall response rate was 17% (95% CI 4-30%). The major grade 3/4 toxicities were neutropenia (26%) and diarrhea (18%).

CONCLUSIONS: Biweekly IRIS showed the moderate activity as salvage treatment in AGC. Considering high neutropenia and gastrointestinal toxicity, patient selection should be warranted; serum albumin may be a predictive factor for treatment decision
Files in This Item:
T201103218.pdf Download
DOI
10.1007/s00280-011-1560-9
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pharmacology (약리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Hyo Song(김효송) ORCID logo https://orcid.org/0000-0002-0625-9828
Noh, Sung Hoon(노성훈) ORCID logo https://orcid.org/0000-0003-4386-6886
Roh, Jae Kyung(노재경)
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
Park, Hyung Soon(박형순)
Shin, Sang Joon(신상준) ORCID logo https://orcid.org/0000-0001-5350-7241
Chon, Hong Jae(전홍재)
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
Jeung, Hei Cheul(정희철) ORCID logo https://orcid.org/0000-0003-0952-3679
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/94058
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links